Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China National Medicines Corporation Ltd. (600511.SS)
CNY28.00
+0.34 (+1.23%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 12 A, Sanyuan West Alley 100077
Beijing, CN
Beijing, CN
CEO
Fei Chen
Website
cncm.com.cn
IPO
2002-11-27
ISIN CNE000001D56
Description
China National Medicines Corporation Ltd., in conjunction with its various operating entities, is a prominent player in the distribution of pharmaceutical goods across China. The enterprise's scope extends to the production and commercialization of innovative as well as pre-existing drug formulations. Additionally, it markets both traditional Chinese patent remedies and modern Western medications, alongside a range of medical apparatus. Complementing these activities, the firm delivers warehousing solutions and acts as an agent for import and export transactions. Its diverse clientele encompasses hospitals, retail pharmacies, and other healthcare organizations. Established in 1999, the company maintains its principal office in Beijing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY28.00
+0.34 (+1.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.18
Float Shares
441.90M
Free Float %
58.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.37% | +1.73% | -3.80% | -5.84% | -4.60% | -4.10% | -8.13% | -29.72% | -24.30% | +0.58% | +1,016.19% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
28.00
DCF (Unlevered)
66.00
+135.7%
DCF (Levered)
83.46
+198.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.61
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.7% Q1'26: +6.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+0.0% Q1'26: +3.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.7% ★ Q1'26: -26.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+5.0% Q1'26: +3.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+15.7% ★ Q1'26: +9.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.60× ★ Q1'26: 1.65× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.08B
est: 12.55B (-3.8%)
|
34.61B
est: 15.90B (+117.7%)
|
36.28B
est: 35.26B (+2.9%)
|
38.74B
est: 39.43B (-1.8%)
|
44.64B
est: 42.51B (+5.0%)
|
40.38B
est: 44.95B (-10.2%)
|
46.47B
est: 45.71B (+1.7%)
|
45.50B
est: 48.31B (-5.8%)
|
49.70B
est: 50.31B (-1.2%)
|
50.60B
est: 52.48B (-3.6%)
|
52.47B
est: 52.90B (-0.8%)
|
55.34B
54.76B – 55.92B
+4.6% YoY
|
58.34B
57.12B – 59.55B
+5.4% YoY
|
60.85B
59.92B – 61.78B
+4.3% YoY
|
| EBITDA |
585.65M
est: 589.35M (-0.6%)
|
1.60B
est: 746.54M (+114.5%)
|
1.80B
est: 1.66B (+8.7%)
|
1.93B
est: 1.85B (+4.3%)
|
2.37B
est: 2.00B (+18.6%)
|
1.67B
est: 2.11B (-20.9%)
|
2.15B
est: 2.15B (+0.4%)
|
2.42B
est: 2.27B (+6.8%)
|
2.49B
est: 2.50B (-0.4%)
|
2.21B
est: 2.60B (-14.9%)
|
2.87B
est: 2.62B (+9.2%)
|
2.74B
2.72B – 2.77B
+4.6% YoY
|
2.89B
2.83B – 2.95B
+5.4% YoY
|
3.02B
2.97B – 3.06B
+4.3% YoY
|
| EBIT |
543.75M
est: 560.60M (-3.0%)
|
1.53B
est: 710.13M (+114.8%)
|
1.72B
est: 1.57B (+9.2%)
|
1.84B
est: 1.76B (+4.7%)
|
2.27B
est: 1.90B (+19.5%)
|
1.57B
est: 2.01B (-22.0%)
|
2.05B
est: 2.04B (+0.7%)
|
2.32B
est: 2.16B (+7.5%)
|
2.37B
est: 2.36B (+0.5%)
|
2.10B
est: 2.46B (-14.5%)
|
2.63B
est: 2.48B (+5.9%)
|
2.60B
2.57B – 2.62B
+4.6% YoY
|
2.74B
2.68B – 2.79B
+5.4% YoY
|
2.85B
2.81B – 2.90B
+4.3% YoY
|
| Net Income |
512.85M
est: 867.68M (-40.9%)
|
990.19M
est: 953.19M (+3.9%)
|
1.14B
est: 1.09B (+4.3%)
|
1.40B
est: 1.28B (+9.5%)
|
1.60B
est: 1.51B (+6.2%)
|
1.38B
est: 1.64B (-15.7%)
|
1.75B
est: 1.71B (+2.6%)
|
1.96B
est: 1.93B (+1.7%)
|
2.15B
est: 2.16B (-0.7%)
|
2.00B
est: 2.25B (-10.9%)
|
2.00B
est: 2.01B (-0.8%)
|
2.10B
2.04B – 2.19B
+4.3% YoY
|
2.23B
2.11B – 2.41B
+6.1% YoY
|
2.33B
2.28B – 2.38B
+4.6% YoY
|
| SGA |
383.93M
est: 365.71M (+5.0%)
|
794.50M
est: 463.26M (+71.5%)
|
1.02B
est: 1.03B (-1.1%)
|
1.39B
est: 1.15B (+20.9%)
|
1.44B
est: 1.24B (+15.9%)
|
1.37B
est: 1.31B (+4.8%)
|
1.33B
est: 1.33B (-0.3%)
|
1.36B
est: 1.41B (-3.1%)
|
1.40B
est: 1.19B (+18.1%)
|
1.26B
est: 1.24B (+1.3%)
|
342.39M
est: 1.25B (-72.6%)
|
1.31B
1.29B – 1.32B
+4.6% YoY
|
1.38B
1.35B – 1.41B
+5.4% YoY
|
1.44B
1.42B – 1.46B
+4.3% YoY
|
| EPS |
1.07
est: 1.15 (-7.0%)
|
1.43
est: 1.26 (+13.2%)
|
1.55
est: 1.45 (+6.9%)
|
1.83
est: 1.70 (+7.6%)
|
2.11
est: 2.00 (+5.4%)
|
1.83
est: 2.17 (-15.8%)
|
2.32
est: 2.27 (+2.4%)
|
2.60
est: 2.56 (+1.6%)
|
2.84
est: 2.87 (-0.9%)
|
2.65
est: 2.98 (-11.0%)
|
2.65
est: 2.68 (-1.1%)
|
2.81
2.71 – 2.91
+4.7% YoY
|
3.00
2.79 – 3.20
+6.8% YoY
|
3.09
3.02 – 3.15
+2.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
276.56M
OE per share TTM
0.37
Owner's Yield
1.33%
Maintenance CapEx ratio
1.83%
Maint CapEx / Avg PPE
1.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 30 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.08% | 30.2K | 0.65% |
| 2 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.05% | 176.5K | 0.44% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.03% | 4.5K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.02% | 17.0K | 0.55% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 220.9K | 0.19% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 41.6K | 0.44% |
| 7 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 111.8K | 0.46% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 238.4K | 0.39% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 187.4K | 0.29% |
| 10 | JPMorgan BetaBuilders Emerging Markets Equity ETF BBEM | 0.00% | 13.9K | 0.15% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
846.4K
Shares Outstanding
754.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Fei | Chief Financial Officer | — | male |
| Fei Chen | Chief Financial Officer | — | male |
| Lei Tang | Deputy General Manager | — | male |
| Lichun Luo | General Counsel, Secretary of the Board & Chief Compliance Officer | — | female |
| Ting Zhang | Employee Director | — | female |
| Tong Ye | Deputy General Manager | — | female |
| Xinlei Li | Accounting Supervisor | — | — |
| Yuetao Liu | Chairman & Acting GM | — | male |
| Zhang Ting | Deputy Secretary of the Party Committee | — | female |
| Zhuo Yuan Xiao | Deputy General Manager | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600511.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
